Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + Golcadomide for Front-line Treatment of Frail Older DLBCL Patients
2023-506206-38-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and golcadomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
rituximabgolcadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-506206-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506206-38-00.